医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Vivimed Life Sciences Pvt Ltd Issues Voluntary Nationwide Recall of Losartan Potassium 25 mg, 50 mg and 100 mg Tablets, USP Due to the Detection of Trace Amounts of N-Nitroso-N-methyl-4-aminobutyric acid (NMBA) Impurity

2019年05月04日 AM12:10
このエントリーをはてなブックマークに追加


 

CHENNAI, India

Vivimed Life Sciences Pvt Ltd (Vivimed) is recalling 19 lots of Losartan Potassium Tablets USP 25 mg, 50 mg, and 100 mg to consumer level. Due to the detection of an impurity – N-Nitroso-N-methyl-4-aminobutyric acid (NMBA) – that is above the US Food & Drug Administration’s interim acceptable exposure limit of 9.82 ppm. Based on the available information, the risk of developing cancer in a few patients following long-term use of the product containing high levels of the impurity NMBA cannot be ruled out.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190503005346/en/

25 mg 90s label for Heritage (Graphic: Business Wire)

25 mg 90s label for Heritage (Graphic: Business Wire)

This product is made by Vivimed at its Plant in Alathur, Chennai, India and Distributed by Heritage Pharmaceuticals Inc, East Brunswick NJ (Heritage). To date, neither Vivimed nor Heritage has received any reports of adverse events related to this recall.

Losartan Potassium is indicated for the treatment of hypertension, hypertensive patients with left ventricular hypertrophy, nephropathy in Type 2 diabetic patients and is packaged in 90-count and 1000-count bottles. The lots were manufactured by Vivimed at its Plant in Alathur, Chennai, India and Distributed by Heritage Pharmaceuticals Inc, East Brunswick NJ (Heritage).

The identifying NDC #s associated with Heritage distributed product are as follows:

Losartan Tablets 25 mg: 90- count: NDC 23155-644-09, Losartan Tablets 50 mg: 90- count: NDC 23155-645-09; 1000-count: NDC 23155-645-10, Losartan Tablets 100 mg: 90-count- NDC 23155-646-09 1000-count: NDC 23155-646-10.

The affected Losartan Potassium tablets, includes the 19 lot numbers which are listed below:

                         
Product Name     Lot Number     Pack     Expiry Date     Distributed by
Losartan Potassium Tablets USP, 25 mg     CLO17006A     90’s     Nov 2019     HERITAGE
Losartan Potassium Tablets USP, 50 mg     CLO17007A     1000′s     Nov 2019     HERITAGE
Losartan Potassium Tablets USP, 50 mg     CLO17008A     1000′s     Nov 2019     HERITAGE
Losartan Potassium Tablets USP, 50 mg     CLO17009A     1000′s     Nov 2019     HERITAGE
Losartan Potassium Tablets USP, 50 mg     CLO17009B     90′s     Nov 2019     HERITAGE
Losartan Potassium Tablets USP, 50 mg     CLO17010A     90′s     Nov 2019     HERITAGE
Losartan Potassium Tablets USP, 100 mg     CLO17012A     90′s     Nov 2019     HERITAGE
Losartan Potassium Tablets USP, 100 mg     CLO17013A     90′s     Nov 2019     HERITAGE
Losartan Potassium Tablets USP, 100 mg     CLO17014A     1000′s     Dec 2019     HERITAGE
Losartan Potassium Tablets USP, 100 mg     CLO17015A     1000′s     Jan 2020     HERITAGE
Losartan Potassium Tablets USP, 100 mg     CLO17016A     1000′s     Jan 2020     HERITAGE
Losartan Potassium Tablets USP, 100 mg     CLO17017A     1000′s     Jan 2020     HERITAGE
Losartan Potassium Tablets USP, 100 mg     CLO18001A     1000′s     Jan 2020     HERITAGE
Losartan Potassium Tablets USP, 100 mg     CLO18002A     90′s     Jan 2020     HERITAGE
Losartan Potassium Tablets USP, 100 mg     CLO18002B     1000′s     Jan 2020     HERITAGE
Losartan Potassium Tablets USP, 100 mg     CLO18020A     90′s     Apr 2020     HERITAGE
Losartan Potassium Tablets USP, 100 mg     CLO18021A     90′s     Apr 2020     HERITAGE
Losartan Potassium Tablets USP, 100 mg     CLO18022A     90′s     Apr 2020     HERITAGE
Losartan Potassium Tablets USP, 50 mg     CLO18023A     90′s     Apr 2020     HERITAGE
               

Losartan Potassium Tablets were distributed Nationwide to Wholesalers, Distributors, Retail Pharmacies, and Mail Order Pharmacies.

Inmar is notifying distributors and other customers by recall notification and arranging for return of recalled product of Losartan Potassium Tablets from the above lots.

Consumers should contact their doctor for further guidance and potential change of treatment before they stop taking the product. Pharmacies and healthcare facilities that have the product being recalled from above listed lots should stop using and dispensing the product immediately. Consumers should contact their physician or healthcare provider if they have experienced any problems that may be related to taking or using this drug product.

Consumers with questions regarding this recall can contact Vivimed c/o Inmar at 1-877-861-3811 Monday – Friday, 9am – 5pm EST.

Adverse reactions or quality problems associated with the use of this product may be reported to FDA’s MedWatch Adverse Event Reporting program either by phone, online, by regular mail or by fax.

This recall is being conducted with the knowledge of the U.S. Food and Drug Administration.

View source version on businesswire.com: https://www.businesswire.com/news/home/20190503005346/en/

CONTACT

Consumers

Vivimed Life Sciences Pvt Ltd
C/O Inmar Inc
Email: rxrecalls@inmar.com
1-877-861-3811

Media

Inmar Inc
Contact Name: Mr. Jack Patterson
Phone#
1-877-861-3811
Email: rxrecalls@inmar.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • GEDmatch与基因组公司Verogen合作
  •  Genetron Health Announces Strategic Collaboration with CStone
  • PCIファーマ・サービシズが英国トレデガー施設の開発・製造能力を拡大するための大規模投資を発表
  • 21St Century Oncology to Join Australia’s GenesisCare in a Partnership to Increase Access to High Quality Cancer Care in U.S. Communities
  • Konkuk University Research Team Identifies Drought-tolerant Process of Plants at the Molecular Level